The use of this additional molecular analysis has allowed for the further stratification of normal cytogenetics AML into groups with better and worse prognosis, guiding their clinical treatment. Mutations in fms-related tyrosine kinase 3 (FLT3) confer a worse prognosis, while mutations in nucleophosmin (NPM1) and CCAAT/enhancer-binding protein α (CEBPα) predict for prolonged remissions with chemotherapy alone. The gene discussed is FLT3; the disease is acute myeloid leukemia.